Consonance Capital Management as of June 30, 2015
Portfolio Holdings for Consonance Capital Management
Consonance Capital Management holds 28 positions in its portfolio as reported in the June 2015 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Retrophin | 11.3 | $113M | 3.4M | 33.15 | |
| Insys Therapeutics | 10.8 | $107M | 3.0M | 35.92 | |
| Eagle Pharmaceuticals (EGRX) | 9.6 | $96M | 1.2M | 80.86 | |
| Abbvie (ABBV) | 8.8 | $87M | 1.3M | 67.19 | |
| Akorn | 8.1 | $81M | 1.8M | 43.66 | |
| United Therapeutics Corporation (UTHR) | 6.8 | $67M | 387k | 173.95 | |
| Cardiovascular Systems | 6.6 | $66M | 2.5M | 26.45 | |
| Biosante Pharmaceuticals (ANIP) | 6.6 | $66M | 1.1M | 62.05 | |
| Orthofix International Nv Com Stk | 5.7 | $57M | 1.7M | 33.12 | |
| Enanta Pharmaceuticals (ENTA) | 5.6 | $56M | 1.2M | 44.99 | |
| Pacific Biosciences of California (PACB) | 3.1 | $31M | 5.4M | 5.76 | |
| Clovis Oncology | 2.7 | $27M | 303k | 87.88 | |
| Osiris Therapeutics | 2.3 | $23M | 1.2M | 19.46 | |
| Catalyst Pharmaceutical Partners (CPRX) | 2.3 | $23M | 5.5M | 4.13 | |
| Celldex Therapeutics | 1.9 | $19M | 752k | 25.22 | |
| Epirus Biopharmaceuticals In | 1.3 | $13M | 2.3M | 5.71 | |
| Derma Sciences | 1.3 | $13M | 1.8M | 7.16 | |
| Healthways | 1.2 | $12M | 1.0M | 11.98 | |
| Adma Biologics (ADMA) | 1.0 | $9.6M | 1.0M | 9.26 | |
| Vericel (VCEL) | 0.8 | $8.4M | 2.4M | 3.57 | |
| Nanostring Technologies (NSTGQ) | 0.7 | $6.9M | 449k | 15.42 | |
| Merus Labs Intl | 0.4 | $3.8M | 1.6M | 2.33 | |
| Veracyte (VCYT) | 0.3 | $3.3M | 299k | 11.14 | |
| Sientra | 0.3 | $3.3M | 132k | 25.23 | |
| BioTime | 0.2 | $2.4M | 656k | 3.63 | |
| Imprivata | 0.2 | $1.6M | 96k | 16.36 | |
| Biolase Technology | 0.1 | $1.2M | 668k | 1.74 | |
| eHealth (EHTH) | 0.0 | $67k | 5.2k | 12.78 |
